On this page of StockholderLetter.com we present the 11/8/2023 shareholder letter from MEI Pharma, Inc. — ticker symbol MEIP. Reading current and past MEIP letters to shareholders can bring important insights into the investment thesis.

 •  11/8/2023 Letter Continued (Full PDF)
 •  12/20/2024 MEIP Stockholder Letter
 •  12/30/2025 MEIP Stockholder Letter

MEIP 11/8/2023 Shareholder/Stockholder Letter Transcript:

focusED on:


2 clinical oncology
CANDIDATES
2023 ANNUAL REPORT


focusED on:


EFFORTS TO    
DELIVER BENEFITS    
TO PATIENTS
2023 ANNUAL REPORT


focusED on:


DATA DRIVEN
DECISIONS
2023 ANNUAL REPORT


focusED on:


CREATING VALUE
2023 ANNUAL REPORT



OUR LEADERSHIP
focusED on:
Dear Shareholders
What is most rewarding about working in the biopharmaceutical industry is the opportunity
to develop therapies that can benefit patients. Our business at MEI Pharma is to develop
cancer therapies that address meaningful unmet medical needs, that if successful,    
would present valuable commercial opportunities and in turn create significant value    
for our stockholders.

"It   s rewarding to have the
opportunity to lead the
company as we advance
novel therapies that can
benefit patients with cancer.
We are now just months
away from reporting first in
human data combining
voruciclib, our CDK9
inhibitor, with Venclexta  
and ME-344, our
mitochondrial inhibitor,
combined with Avastin  ."
David M. Urso, JD
President and CEO

MEI PHarma
I assumed the role of MEI   s President and CEO in June 2023, inspired to lead the Company   s
two clinical stage oncology drug development programs, voruciclib and ME-344. At the time,
a proposed acquisition of Infinity Pharmaceuticals was pending to augment the pipeline with
a later-stage clinical asset in an area of significant company expertise. While we believed the
potential upside of the Infinity merger was compelling for stockholders, the transaction,
ultimately, was not approved by a narrow margin. We value the views of our stockholders,
and since the termination of the merger we've turned our focus fully toward advancing our
two promising clinical-stage programs - which are both now a year more advanced - as a
standalone company.
We expect to report clinical data during the first half of 2024 that will help inform the
potential of each program to benefit patients and to create value for our stockholders.    
We are just months away from reporting the first human data for voruciclib, a CDK9 inhibitor,
combined with Venclexta   (venetoclax) in patients with relapsed/refractory AML, and for
ME-344, a mitochondrial inhibitor, combined with Avastin   (bevacizumab) in patients with
previously treated metastatic colorectal cancer. We expect to report data from the dose
escalation portion of the Phase 1 clinical trial evaluating voruciclib plus Venclexta in early
calendar 2024, and data from Cohort 1 of the Phase 1b clinical trial evaluating ME-344 plus
Avastin in the first half of 2024.
The programs represent differentiated and novel drug combinations with the potential to
overcome resistance mechanisms to two standard-of-care therapies: the BCL2 inhibitor
Venclexta in the case of voruciclib and the VEGF inhibitor Avastin in the case of ME-344.    
We chose these combination approaches based on strong scientific hypotheses to address
known resistance mechanisms of each standard-of-care therapy, clear medical need and    
the consequent significant commercial opportunities associated with each program.
2023 ANNUAL REPORT



 11/8/2023 Letter Continued (Full PDF)